TY - JOUR
T1 - Prognostic value of metabolic tumor volume and total lesion glycolysis from18F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma
AU - Liu, Dou Dou
AU - Li, Jianfang
AU - Li, Xiaomao
AU - Xie, Liangjun
AU - Qin, Luping
AU - Peng, Fangyu
AU - Cheng, Mu Hua
N1 - Publisher Copyright:
© 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
PY - 2019/11
Y1 - 2019/11
N2 - Objective: To investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), measured by preoperative18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), in risk stratification of patients with endometrial carcinoma (EC). Methods: The patients with pathological diagnosis of EC who underwent preoperative 18 F-FDG PET/CT imaging were retrospectively selected for analysis of the prognostic values of PET parameters in risk classification and lymph node metastases (LNMs). Receiver-operating-characteristic analysis was used to analyze the correlation of PET parameters cutoff values with deep myometrial invasion (MI), lymphovascular space involvement and LNM for prognostic values in risk stratification. Results: The sensitivity, specificity, positive predictive value, negative predictive value and accuracy for detection of LNM are 83.3%, 99.7%, 90.9%, 99.5% and 99.2%, respectively. The MTV and TLG of primary lesion of EC in the patients with LNM are notably higher than those in patients without LNM, p<0.010. The MTV and TLG of the EC primary lesions in high-risk patients are significantly higher than those in low-risk patients (p<0.010), but the maximum standardized uptake value (SUVmax) is not. The MTV and TLG of primary lesions were superior to SUVmax for predicting of deep MI, LNM and high-risk of EC (p<0.005). Conclusion: MTV and TLG of primary lesions are more valuable in predicting risk stratification of EC patients. Preoperative18F-FDG PET/CT imaging is useful in predicting the LNM of EC and may help guide pelvic lymphadenectomy to avoid unnecessary pelvic lymphadenectomy in EC patients with low-risk stratification.
AB - Objective: To investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), measured by preoperative18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), in risk stratification of patients with endometrial carcinoma (EC). Methods: The patients with pathological diagnosis of EC who underwent preoperative 18 F-FDG PET/CT imaging were retrospectively selected for analysis of the prognostic values of PET parameters in risk classification and lymph node metastases (LNMs). Receiver-operating-characteristic analysis was used to analyze the correlation of PET parameters cutoff values with deep myometrial invasion (MI), lymphovascular space involvement and LNM for prognostic values in risk stratification. Results: The sensitivity, specificity, positive predictive value, negative predictive value and accuracy for detection of LNM are 83.3%, 99.7%, 90.9%, 99.5% and 99.2%, respectively. The MTV and TLG of primary lesion of EC in the patients with LNM are notably higher than those in patients without LNM, p<0.010. The MTV and TLG of the EC primary lesions in high-risk patients are significantly higher than those in low-risk patients (p<0.010), but the maximum standardized uptake value (SUVmax) is not. The MTV and TLG of primary lesions were superior to SUVmax for predicting of deep MI, LNM and high-risk of EC (p<0.005). Conclusion: MTV and TLG of primary lesions are more valuable in predicting risk stratification of EC patients. Preoperative18F-FDG PET/CT imaging is useful in predicting the LNM of EC and may help guide pelvic lymphadenectomy to avoid unnecessary pelvic lymphadenectomy in EC patients with low-risk stratification.
KW - Endometrial Carcinoma
KW - Lymphatic Metastases
KW - Metabolism
KW - Risk Assessment
KW - Tumor Volume
UR - http://www.scopus.com/inward/record.url?scp=85072847651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072847651&partnerID=8YFLogxK
U2 - 10.3802/jgo.2019.30.e89
DO - 10.3802/jgo.2019.30.e89
M3 - Article
C2 - 31576685
AN - SCOPUS:85072847651
SN - 2005-0380
VL - 30
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 6
M1 - e89
ER -